Abstract
Chronotherapy consists in the adaption of chemotherapeutic drug delivery to circadian (~ 24h) rhythms. This can be achieved in fully ambulatory patients using multichannel programmable pumps.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Redfern and B. Lemmer: Handbook of Experimental Pharmacology. Vol. 125: Physiology and Pharmacology of Biological Rhythms. Springer-Verlag, Berlin, 1997, 668 pp.
Lévi F.: Chronopharmacology of anticancer agents. Chapt. 11. In: Handbook of Experimental Pharmacology. Vol.:Physiology and Pharmacology of Biological Rhythms. P.H. Redfern and B. Lemmer eds, Springer-Verlag, Berlin, pp. 299–331, 1997.
Hrushesky W.J.M., Langevin T., Kim Y.J., Wood PA.: Circadian dynamics of tumor necrosis factor a (cachectin) lethality. J. Exp. Med., 1994, 180: 1059–1065.
Boughattas N., Lévi F., Fournier C., Lemaigre G., Roulon A., Hecquet B., Mathé G., Reinberg A.: Circadian rhythm in toxicities and tissue uptake of 1,2diamminocyclohexane (trans-1) oxalatoplatinum (II) in mice. Cancer Res., 1989, 49: 3362–3368.
Ohdo S., Makinosumi T., Ishizaki T., Yukawa E., Higuchi S., Nakano S., Ogawa N.: Cell cycle-dependent chronotoxicity of irinotecan hydrochloride in mice. J. Pharmacol. Exp. Ther., 1997, 283: 1383–1388.
Filipski E., Breillout F., Lévi F.: Relationship between circadian rhythm of vinorelbine toxicity and efficacy in P388-bearing mice. J. Pharm. Exp. Ther., sous presse.
Tampellini M., Filipski E., Liu X-H, Li X-M, François E, Lévi F: Circadian rhythm in docetaxel tolerability and efficacy in mice. Cancer Res., 1998, 58: 3896–3904.
Lévi F.: Chronotherapy for gastrointestinal cancers. Curr. Opin. Oncol., 1996, 8: 334–341.
Li X.M., Metzger G., Filipski E. et al.: Pharmacologic modulation of reduced glutathione (GSH) circadian rhythms by buthionine sulfoximine (BSO): relationship with cisplatin (CDDP) toxicity in mice. Toxicol. Appl. Pharmacol., 1997, 143: 281–290.
Lévi F., Giacchetti S.: Chronomodulation of chemotherapy against metastatic colorectal cancer. In: Management of Colorectal Cancer. H. Bleiberg, P. Rougier and H.J. Wilke Eds, Martin Dunitz Publishers, London, 1997, 289–306.
Caussanel J.P., Lévi F., Brienza S. et al.: Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J. Natl Cancer Inst., 1990, 82: 1046–1050.
Lévi F., Misset J.L., Brienza S. et al.: A chronopharmacologic Phase II clinical trial with 5-fluorouracil, folinic acid and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer, 1992, 69: 893–900.
Bertheault-Cvitkovic F., Jami A., Ithzaki M. et al.: Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with metastatic colorectal cancer. J. Clin. Oncol., 1996, 14 (11): 2950–2958.
Lévi F., Zidani R., Vannetzel J.M. et al.: Chronomodulated versus fixed infusion rate delivery of ambulatory chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with colorectal cancer metastases. A randomized multiinstitutional trial. J. Natl. Cancer Inst., 1994, 86: 1608–1617.
Lévi F., Zidani R., Misset J.L. for the Int. Org. for Cancer Chronother.: Randomized multicentre trial of chronotherapy with oxaliplatin, fluorouracil,and folinic acid in metastatic colorectal cancer. Lancet, 1997, 350: 681–686.
Lévi F., Zidani R., Brienza S. et al. for the International Organization for Cancer Chronotherapy: A multicenter evaluation of intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil and leucovorin as initial treatment of patients with metastatic colorectal cancer. Submitted for publication.
Lévi F., Zidani R., Giacchetti S., Llory J.F., Dogliotti L., Perpoint B., Chollet P., Focan C. for the I.O.C.C.: First line chemotherapy with 5-fluorouracil (5-FU), leucovorin, and oxaliplatin (1-OHP) (FLO) against metastatic colorectal cancer (MCC): relationship between chronotherapy, dose intensity (DI), response and survival. Proc. 34th Ann. Meeting Am. Soc. Clin. Oncol., 1998, abstr. 1044.
Bismuth H., Adam R., Lévi F et al.: Resection of initially unresectable liver metastases from colorectal cancer following systemic chemotherapy. Ann. Surg., 1996,, 224 (4): 509–522.
Giacchetti S., Itzhaki M., Gruia G et al.: Long term survival of patients with unresectable colorectal liver metastases following infusional chemotherapy with 5fluorouracil, folinic acid, oxaliplatin and surgery. Submitted for publication.
Giacchetti S., Zidani R., Perpoint B., Pinel M.C., Faggiuolo R., Focan C., Letoumeau Y., Chollet P., Llory J.F., Coudert B., Bertheault-Cvitkovic F., Adam R., Le Bail N., Misset J.L., Bayssas M., Lévi F.: Phase III trial of 5-fluorouracil (5-FU), folinic acid (FA), with or without oxaliplatin (OXA) in previously untreated patients (pts) with metastatic colorectal cancer (MCC). Proc. 33rd Annual Meeting Am. Soc. Clin. Oncol„ May 17–20, 1997, Denver, CO, U.S.A., abstr. # 805.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer Science+Business Media New York
About this chapter
Cite this chapter
Lévi, F. et al. (2002). Chronotherapy of Colorectal Liver Metastases. In: Habib, N.A. (eds) Multi-Treatment Modalities of Liver Tumours. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0547-1_21
Download citation
DOI: https://doi.org/10.1007/978-1-4615-0547-1_21
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-5126-9
Online ISBN: 978-1-4615-0547-1
eBook Packages: Springer Book Archive